NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report report published on Saturday morning. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets reduced their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY stock opened at $0.61 on Friday. The stock’s fifty day moving average price is $0.65 and its two-hundred day moving average price is $0.62. The company has a market cap of $2.96 million, a PE ratio of -0.01 and a beta of 0.67. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.